Blood pressure control in patients with chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Chronic kidney disease (CKD) involves kidney damage or reduced eGFR for over 3 months.
• Cardiovascular disease (CVD) poses a significant risk to CKD patients, increasing morbidity and mortality.
• The renin-angiotensin system (RAS) plays a vital role in CKD progression and the hypertension-renal disease link.

Purpose of the Study:

• To outline the importance of blood pressure control in CKD patients.
• To highlight the role of RAS inhibitors in managing hypertension and protecting renal function.
• To define target blood pressure goals and additional antihypertensive strategies for CKD.

Main Methods:

• Review of current definitions and classifications of CKD.
• Analysis of the relationship between CKD and cardiovascular disease.
• Examination of the role of the renin-angiotensin system in CKD.
• Discussion of first-line antihypertensive agents (RAS inhibitors) and their renoprotective effects.
• Specification of target blood pressure levels based on urinary protein excretion.

Main Results:

• Blood pressure control is essential for preventing CVD and renoprotection in CKD.
• RAS inhibitors (ACE inhibitors and ARBs) are primary agents for blood pressure management and offer renoprotection.
• Target blood pressure in CKD is <130/80 mm Hg, or <125/75 mm Hg with >1 g/day proteinuria.
• Combination therapy with other antihypertensives may be necessary to achieve target blood pressure.

Conclusions:

• Effective blood pressure management, particularly with RAS inhibitors, is critical for improving outcomes in CKD patients.
• Achieving specific blood pressure targets can mitigate cardiovascular risks and preserve kidney function.
• A multi-agent approach to antihypertensive therapy is often required for optimal patient management.